Osaic Holdings Inc. Purchases 2,158 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Osaic Holdings Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 132.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,787 shares of the biopharmaceutical company’s stock after acquiring an additional 2,158 shares during the quarter. Osaic Holdings Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,202,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Evelyn Partners Investment Management LLP raised its stake in Alnylam Pharmaceuticals by 11.5% during the second quarter. Evelyn Partners Investment Management LLP now owns 290 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 30 shares in the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the last quarter. Bayforest Capital Ltd increased its position in Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 39 shares in the last quarter. MAI Capital Management lifted its stake in Alnylam Pharmaceuticals by 9.2% in the 2nd quarter. MAI Capital Management now owns 488 shares of the biopharmaceutical company’s stock valued at $159,000 after purchasing an additional 41 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in Alnylam Pharmaceuticals by 32.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 179 shares of the biopharmaceutical company’s stock valued at $58,000 after purchasing an additional 44 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In related news, CEO Yvonne Greenstreet sold 10,000 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $451.27, for a total transaction of $4,512,700.00. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,517,119.43. This trade represents a 13.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $452.18, for a total value of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $9,615,155.52. This represents a 36.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 37,778 shares of company stock valued at $17,096,988 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on ALNY shares. JPMorgan Chase & Co. decreased their target price on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research note on Monday, October 13th. Barclays upped their target price on Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Bank of America upped their price target on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 31st. Finally, HC Wainwright set a $570.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Twenty-three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $477.44.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $397.65 on Friday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm’s fifty day moving average price is $433.33 and its two-hundred day moving average price is $416.00. The company has a market capitalization of $52.53 billion, a price-to-earnings ratio of 1,656.88 and a beta of 0.33.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.